Abstract
No public abstract is available from the verified source records.
Milton Packer
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Diastolic dysfunction in congestive heart failure
10.1056/nejm199111283252206 · 1991
Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle
10.1056/nejmoa032566 · 2004
Hypertensive hypertrophic cardiomyopathy of the elderly
10.1056/nejm198501313120504 · 1985
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction
10.1371/journal.pone.0201836 · 2018
Interleukin-6 in patients with heart failure and preserved ejection fraction
10.1016/j.jchf.2023.06.031 · 2023
What causes inflammation in heart failure and preserved ejection fraction? Potential role of eicosanoid adipokines
10.1016/j.jchf.2025.102638 · 2025
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction
10.1007/s00392-011-0305-4 · 2011
Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction
10.1016/j.jacc.2011.11.040 · 2012
Heart failure with preserved ejection fraction: treat now by treating comorbidities
10.1001/jama.300.4.431 · 2008
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
10.1016/j.jacc.2013.02.092 · 2013
Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening
10.1093/cvr/cvy038 · 2018
Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study
10.1161/circulationaha.120.045810 · 2020
Biomarker profiles in heart failure patients with preserved and reduced ejection fraction
10.1161/jaha.116.003989 · 2017
Interleukin 6 and development of heart failure with preserved ejection fraction in the general population
10.1161/jaha.120.018549 · 2021
Al-Kindi SG Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction
10.1016/j.amjcard.2021.11.045 · 2022
Health ABC Study Investigators. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study
10.1016/j.jacc.2009.12.045 · 2010
10.1161/circheartfailure.122.010051
10.1161/circheartfailure.122.010051
Prevalence and correlates of coronary microvascular dysfunction in heart failure and preserved ejection fraction: PROMIS-HFpEF
10.1093/eurheartj/ehy531 · 2018
Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction
10.1093/eurheartj/ehab653 · 2021
Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction
10.1186/s12968-021-00807-3 · 2021
The association of coronary microvascular dysfunction and cardiac maladaptation with clinical outcomes in heart failure with preserved ejection fraction: A prospective dynamic SPECT study
10.1016/j.ijcard.2025.133064 · 2025
Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs
10.1161/circresaha.108.184408 · 2009
Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin
10.1161/circulationaha.114.013215 · 2015
Low myocardial protein kinase G activity in heart failure with preserved ejection fraction
10.1161/circulationaha.111.076075 · 2012
Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction
10.1093/cvr/cvs353 · 2013
cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes
10.1074/jbc.m603416200 · 2006
Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts
10.1161/circulationaha.110.971853 · 2011
From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited
10.1161/circresaha.121.318159 · 2021
Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction
10.1161/circresaha.116.308688 · 2016
Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats
10.1161/hypertensionaha.109.148635 · 2010
Association of inflammatory-hematological biomarkers with hypertension and related comorbidities
10.3390/jcm15062279 · 2026
Integrative inflammation-metabolism indicator for cardiovascular-kidney-metabolic syndrome: evaluating the c-reactive protein-triglyceride glucose index for risk stratification and progression across three national cohorts
10.1155/mi/8912366 · 2026
Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial
10.1161/01.hyp.0000226046.58883.32 · 2006
Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial
10.1001/jama.2009.1347 · 2009
IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity, and associated with liver stiffness and fibrosis in fatty liver disease
10.2337/db23-0171 · 2023
Effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists on inflammatory and metabolic biomarkers in type 2 diabetes: a systematic review and meta-analysis
10.1111/dom.71106 · 2026
The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials
10.1111/dom.15586 · 2024
Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)
10.1186/s12933-025-03014-x · 2025
Central adiposity or hypertension: which drives heart failure with a preserved ejection fraction?
2025
Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction?
2025
Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial
10.1038/s41591-026-04615-z · doi-reference
Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results
10.1016/j.cardfail.2023.04.003 · doi-reference
Acute effects of myeloperoxidase inhibition on exercise hemodynamics in heart failure with preserved ejection fraction: a randomized clinical trial
10.1016/j.mayocp.2025.02.022 · doi-reference
Bayés-Genís A. Colchicine in acutely decompensated heart failure: the COLICA trial
10.1093/eurheartj/ehae538 · doi-reference
Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial
10.1002/art.41095 · doi-reference
IL-1 blockade in patients with heart failure with preserved ejection fraction
10.1161/circheartfailure.118.005036 · doi-reference
Evolutionary history of the comorbidity-driven coronary microvascular endothelial inflammation hypothesis and its metamorphosis to the adipokine hypothesis of heart failure with a preserved ejection fraction
10.1016/j.jchf.2025.102822 · doi-reference
Causal role of adipose tissue-derived adipokines in the pathogenesis of heart failure with preserved ejection fraction: experimental demonstration as the basis for clinical targeting
10.1093/eurheartj/ehag029 · doi-reference
Adipocyte-specific deletion of IL-6 does not attenuate obesity-induced weight gain or glucose intolerance in mice
10.1152/ajpendo.00206.2019 · doi-reference
Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis
10.1016/j.cyto.2010.06.013 · doi-reference
IL-6 biology: implications for clinical targeting in rheumatic disease
10.1038/nrrheum.2014.127 · doi-reference
Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review
10.1155/2010/513948 · doi-reference
Myocardial gene expression signatures in human heart failure with preserved ejection fraction
10.1161/circulationaha.120.050498 · doi-reference
Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure
10.1161/circulationaha.118.038010 · doi-reference
10.1161/01.cir.0000077913.60364.d2
10.1161/01.cir.0000077913.60364.d2 · doi-reference
Interleukin-1 signalling inhibitors in heart failure with preserved and reduced ejection fraction
10.18087/cardio.2025.11.n2995 · doi-reference
Interleukin 6 signalling in heart failure with preserved and reduced ejection fraction
10.18087/cardio.2024.3.n2534 · doi-reference
Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study
10.1161/circheartfailure.113.000344 · doi-reference
10.1038/s41598-022-24226-1
10.1038/s41598-022-24226-1 · doi-reference
Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum
10.1038/s41598-024-65667-0 · doi-reference
Targeting IL-6 trans-signalling: past, present and future prospects
10.1038/s41577-023-00856-y · doi-reference
Obesity Is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation
10.1371/journal.pone.0133494 · doi-reference
IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?
10.1210/jcem.87.3.8351 · doi-reference
Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation
10.2337/diabetes.52.5.1104 · doi-reference
Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2
10.1371/journal.pbio.3000967 · doi-reference
gp130 plays a critical role in pressure overload-induced cardiac hypertrophy
10.1074/jbc.m100814200 · doi-reference
Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1beta upregulation via nuclear factor kappaB activation
10.1161/jaha.113.000267 · doi-reference
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
10.1161/01.cir.0000124490.27666.b2 · doi-reference
Inflammatory macrophage interleukin-1β mediates high-fat diet-induced heart failure with preserved ejection fraction
10.1016/j.jacbts.2022.08.003 · doi-reference
Interleukin-1beta disruption protects male mice from heart failure with preserved ejection fraction pathogenesis
10.1161/jaha.122.029668 · doi-reference
Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state
10.1161/circulationaha.106.643585 · doi-reference
Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells
10.1152/ajpregu.00207.2009 · doi-reference
IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis
10.1093/cvr/cvy013 · doi-reference
Interleukin-6 blockade reduces salt-induced cardiac inflammation and fibrosis in subtotal nephrectomized mice
10.1152/ajprenal.00396.2021 · doi-reference
Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging
10.3899/jrheum.131540 · doi-reference
Interleukin-6 blockade modulates monocyte recruitment to protect against diastolic dysfunction associated with inflammatory arthritis
10.1186/s13075-025-03700-x · doi-reference
Interleukin-6 deficiency attenuates angiotensin II-induced cardiac pathogenesis with increased myocyte hypertrophy
10.1016/j.bbrc.2017.10.119 · doi-reference
PPARalpha-NF-kappaB heterodimer mediates obesity-induced diastolic dysfunction through autocrine production of IL-6
10.1172/jci196238 · doi-reference
C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response
10.1161/hypertensionaha.110.158915 · doi-reference
Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice
10.1161/atvbaha.111.229435 · doi-reference